Sensorion SA (EPA:ALSEN)

France · Delayed Price · Currency is EUR

0.374

+0.001 (0.27%)

Apr 28, 2026, 5:35 PM CET

78.54% (1Y)

Market Cap	191.73M
Revenue (ttm)	5.81M
Net Income (ttm)	-29.43M
Shares Out	514.72M
EPS (ttm)	-0.10
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,602,667
Average Volume	2,176,973
Open	0.370
Previous Close	0.373
Day's Range	0.365 - 0.393
52-Week Range	0.210 - 0.808
Beta	0.37
RSI	43.45
Earnings Date	Mar 30, 2026

About Sensorion

Sensorion SA, a biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France. The company develops SENS-501, a dual AAV vector gene therapy development product for restoring hearing in patients with mutations in OTOF gene in Phase 1/2 clinical trials; and SENS-601, a candidate for the treatment of hearing loss caused by mutations of the GJB2 gene in preclinical studies. It is also developing SENS-40, a small molecule in Phase 2b clinical trials to treat sudden sensorineural... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2009

Employees 63

Stock Exchange Euronext Paris

Ticker Symbol ALSEN

Full Company Profile

Financial Performance

In 2025, Sensorion's revenue was 5.81 million, a decrease of -12.61% compared to the previous year's 6.65 million. Losses were -29.43 million, 13.3% more than in 2024.

Financial Statements

News

Sensorion: CEO Nawal Ouzren To Resign

(RTTNews) - Sensorion (ALSEN.PA) announced that Nawal Ouzren, CEO and a Director, is stepping down from both posts due to a personal matter incompatible with serving as Chief Executive Officer. Amit M...

2 months ago - Nasdaq

Sensorion Transcript: Investor Update

Gene therapy and small molecule programs are advancing, with key clinical milestones expected this year. Regulatory progress enables inclusion of younger patients, and financial runway extends to Q1 2026, with ongoing investor interest.

1 year ago - Transcripts

Sensorion Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Sensorion is advancing gene therapies for hearing loss, with SENS-501 in Phase 1/2 showing early safety and behavioral improvements, and GJB2 progressing toward clinical trials. Strategic partnerships, a robust natural history network, and a focus on young patients differentiate its approach.

1 year ago - Transcripts